 |
5 Diseases |  |
2 Trials |
|
2 Trials |  |
16 News |  |
- ||| afuresertib (LAE002) / Laekna Therap, LAE001 / Laekna Therap
Trial completion, Enrollment change, Trial completion date, Metastases: Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC (clinicaltrials.gov) - Aug 18, 2024
P1/2, N=49, Completed, Sponsor: Laekna Limited
Active, not recruiting --> Completed | N=74 --> 49 | Trial completion date: Oct 2024 --> Mar 2024
- | LAE001 / Laekna Therap
Enrollment change, Trial completion date, Trial suspension, Trial primary completion date: A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer (clinicaltrials.gov) - Feb 21, 2024
P1/2, N=33, Suspended, Sponsor: Laekna Limited
Active, not recruiting --> Completed | N=74 --> 49 | Trial completion date: Oct 2024 --> Mar 2024 N=80 --> 33 | Trial completion date: Aug 2022 --> Jun 2025 | Unknown status --> Suspended | Trial primary completion date: Feb 2022 --> Oct 2023
- afuresertib (LAE002) / Laekna Therap, LAE001 / Laekna Therap
A phase I/II efficacy and safety study of LAE001/prednisone and afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following 1-3 lines of standard of care () - Jul 27, 2023 - Abstract #ESMO2023ESMO_3277;
P1/2
Conclusions The combination therapy demonstrated clinical benefit and a tolerable safety profile in mCRPC patients who failed multiple lines of SOC. The preliminary results warrant further evaluation in a phase III pivotal trial.
- || afuresertib (LAE002) / Laekna Therap, LAE001 / Laekna Therap
Enrollment closed, Metastases: Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC (clinicaltrials.gov) - Mar 9, 2023
P1/2, N=74, Active, not recruiting, Sponsor: Laekna Limited
The preliminary results warrant further evaluation in a phase III pivotal trial. Recruiting --> Active, not recruiting
- || afuresertib (LAE002) / Laekna Therap, LAE001 / Laekna Therap
Trial completion date, Trial primary completion date, Metastases: Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC (clinicaltrials.gov) - Dec 2, 2022
P1/2, N=74, Recruiting, Sponsor: Laekna Limited
Recruiting --> Active, not recruiting Trial completion date: Oct 2022 --> Oct 2024 | Trial primary completion date: Sep 2022 --> Oct 2023
- || afuresertib (LAE002) / Laekna Therap, LAE001 / Laekna Therap
Trial completion date, Trial primary completion date, Metastases: Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC (clinicaltrials.gov) - Nov 19, 2021
P1/2, N=74, Recruiting, Sponsor: Laekna Limited
Trial completion date: Oct 2022 --> Oct 2024 | Trial primary completion date: Sep 2022 --> Oct 2023 Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
- afuresertib (LAE002) / Laekna Therap
[VIRTUAL] A phase I dose-escalation study of LAE001/prednisone plus afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following standard of care (SOC) treatment () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1949;
P1/2
The combination therapy of LAE001 75mg BID/prednisone 5mg BID and afuresertib 125mg QD was determined as the RP2D. The preliminary antitumor activity under the RP2D supports the potential clinical benefit for treating dr-mCRPC and moves forward this study to phase II stage.
- abiraterone acetate / Generic mfg.
[VIRTUAL] A phase I dose-escalation study of LAE001 in patients with metastatic castration-resistant prostate cancer (mCRPC) () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1947;
P1/2
The preliminary antitumor activity of LAE001 monotherapy at RP2D level supports the potential clinical benefit of treating pts with mCRPC. Further expansion phase Ib at RP2D is ongoing.
- | LAE001 / Laekna Therap
Enrollment open, Metastases: A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer (clinicaltrials.gov) - Oct 15, 2019
P1/2, N=80, Recruiting, Sponsor: Laekna Limited
Further expansion phase Ib at RP2D is ongoing. Not yet recruiting --> Recruiting
- | afuresertib (LAE002) / Laekna Therap, LAE001 / Laekna Therap
Enrollment open, Metastases: Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC (clinicaltrials.gov) - Sep 18, 2019
P1/2, N=74, Recruiting, Sponsor: Laekna Limited
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | afuresertib (LAE002) / Laekna Therap, LAE001 / Laekna Therap
New P1/2 trial, Metastases: Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC (clinicaltrials.gov) - Aug 19, 2019
P1/2, N=74, Not yet recruiting, Sponsor: Laekna Limited
- | LAE001 / Laekna Therap
New P1/2 trial, Metastases: A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer (clinicaltrials.gov) - Feb 18, 2019
P1/2, N=80, Not yet recruiting, Sponsor: Laekna Limited
- LAE001 / Laekna Therap
Trial termination: A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer (clinicaltrials.gov) - Jul 22, 2016
P1/2, N=31, Terminated, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Completed --> Terminated
- LAE001 / Laekna Therap
Trial primary completion date: A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer (clinicaltrials.gov) - Apr 7, 2016
P1/2, N=31, Completed, Sponsor: Novartis Pharmaceuticals
Completed --> Terminated Trial primary completion date: Jun 2015 --> Feb 2016
- | LAE001 / Laekna Therap
Trial completion, Trial primary completion date: A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer (clinicaltrials.gov) - Mar 8, 2016
P1/2, N=31, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jun 2015 --> Feb 2016 Active, not recruiting --> Completed | Trial primary completion date: Oct 2015 --> Jun 2015
- | LAE001 / Laekna Therap
Enrollment closed, Enrollment change, Trial primary completion date: A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer (clinicaltrials.gov) - Nov 5, 2014
P1/2, N=31, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Oct 2015 --> Jun 2015 Recruiting --> Active, not recruiting | N=75 --> 31 | Trial primary completion date: Jan 2015 --> Oct 2015
- ||| LAE001 / Laekna Therap
Trial initiation date: A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer (clinicaltrials.gov) - Jan 23, 2014
P1/2, N=75, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=75 --> 31 | Trial primary completion date: Jan 2015 --> Oct 2015 Initiation date: Jan 2012 --> Dec 2012
- ||| LAE001 / Laekna Therap
Enrollment change: A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer (clinicaltrials.gov) - Jan 23, 2014
P1/2, N=75, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Jan 2012 --> Dec 2012 N=100 --> 75
- |||| LAE001 / Laekna Therap
Enrollment open: A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer (clinicaltrials.gov) - Mar 6, 2013
P1/2, N=75, Recruiting, Sponsor: Novartis Pharmaceuticals
N=100 --> 75 Not yet recruiting --> Recruiting
- ||||| LAE001 / Laekna Therap
New P1/2 trial: A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer (clinicaltrials.gov) - Jul 22, 2012
P1/2, N=75, Recruiting, Sponsor: Novartis Pharmaceuticals